Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP972275priorityCriticalpatent/ECSP972275A/en
Publication of ECSP972275ApublicationCriticalpatent/ECSP972275A/en
Organic Low-Molecular-Weight Compounds And Preparation Thereof
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Se ha descubierto que los compuestos nuevos de ácido hidroxámico, por ejemplo, de la fórmula I (gráfico), donde R1, R2 y R4 son tales como se definen, resultan de utilidad como fármacos, por ejemplo, para la supreción de liberación del TNF y para el tratamiento de enfermedades autoinmunológicas e inflamatorias, por ejemplo, esclerosis múltiple y artritis reumatoide. Se proporciona métodos para elaborar los compuestos, los intermedios nuevos y las composiciones farmacéuticas que comprenden los compuestos.Novel hydroxamic acid compounds, for example, of formula I (graph), where R1, R2, and R4 are as defined, have been found to be useful as drugs, for example, for suppressing TNF release and for the treatment of autoimmune and inflammatory diseases, for example, multiple sclerosis and rheumatoid arthritis. Methods are provided for making the compounds, the novel intermediates, and the pharmaceutical compositions comprising the compounds.
DERIVATIVES OF THE ESTER AND AMIDA OF THE 2-CAINOPROPANOIC ACID, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH DERIVATIVES TO PREPARE A MEDICINAL PRODUCT
DERIVATIVES OF ACETAMIDE, PROCEDURE TO PREPARE THEM, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THE APPLICATIONS OF SUCH ASANIOLYTICAL COMPOUNDS AND IN THE TREATMENT OF IMMUNO-INFLAMMATORY DISEASES.
Compound derived from piperidinyl, modulator of the activity of chemokine receptors; pharmaceutical composition that includes them; and its use in the treatment of inflammatory, allergic, autoimmune diseases.